Literature DB >> 7589268

Poliomyelitis in The Netherlands: a review of population immunity and exposure between the epidemics in 1978 and 1992.

H C Rümke1, P M Oostvogel, G Van Steenis, A M Van Loon.   

Abstract

An overview of serological and virological studies on poliomyelitis in the Netherlands between two epidemics in 1978 and 1992 is given. Three unvaccinated patients acquired poliomyelitis abroad. In the Netherlands vaccination coverage with quadruple DPT-IPV vaccine is very high. The strong immunogenicity of inactivated poliovirus vaccine was confirmed in a cohort of children, reflected in age-stratified antibody profiles of the population. Adults born in the pre vaccination era appeared in general protected, but 10-25% of persons born between 1930 and 1945 lacked neutralizing antibodies. Revaccination induced a booster type of antibody response in 75-90% of such persons, indicating immunological memory and protection. Virological studies on adopted children from other countries, patients with indications for viral examination, and river waters showed that the Netherlands was regularly exposed to polio virus (PV), without signs of indigenous transmission. Persons found to carry PV or their close contacts had travelled to a PV endemic country. Most of 557 isolates were vaccine-derived, only 8% were wild type viruses. Despite their presence, up to 1992 the well-known susceptibles for PV in the Netherlands were shielded by the herd immunity of the Dutch population.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7589268      PMCID: PMC2271413          DOI: 10.1017/s0950268800058416

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  25 in total

1.  Vaccination against poliomyelitis with live virus vaccines. 7. Effect of previous Salk vaccination on virus excretion.

Authors:  G W DICK; D S DANE; J McALISTER; M BRIGGS; R NELSON; C M FIELD
Journal:  Br Med J       Date:  1961-07-29

2.  The quantitation of poliomyelitis virus in the human alimentary tract with reference to coexisting levels of homologous serum neutralizing antibody.

Authors:  H A HOWE
Journal:  Am J Hyg       Date:  1962-01

3.  New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines.

Authors:  A L van Wezel; G van Steenis; C A Hannik; H Cohen
Journal:  Dev Biol Stand       Date:  1978

4.  Viral and epidemiological links between poliomyelitis outbreaks in unprotected communities in Canada and the Netherlands.

Authors:  J Furesz; R E Armstrong; G Contreras
Journal:  Lancet       Date:  1978-12-09       Impact factor: 79.321

5.  Removal of enteric viruses from surface water at eight waterworks in The Netherlands.

Authors:  M van Olphen; J G Kapsenberg; E van de Baan; W A Kroon
Journal:  Appl Environ Microbiol       Date:  1984-05       Impact factor: 4.792

6.  [Immune status for poliomyelitis, rubella and measles of the Dutch population 10 years or older in 1980; a serological study].

Authors:  M A Conyn-van Spaendonck; C A Hannik; H Bijkerk; L M van Noorle Jansen; A D Plantinga; G van Steenis; A L van Wezel; E J Ruitenberg
Journal:  Ned Tijdschr Geneeskd       Date:  1984-10-06

7.  The spread of wild poliovirus in the well-vaccinated Netherlands in connection with the 1978 epidemic.

Authors:  G J Schaap; H Bijkerk; R A Coutinho; J G Kapsenberg; A L van Wezel
Journal:  Prog Med Virol       Date:  1984

8.  Quantitative relationship of preexisting homotypic antibodies to the excretion of attenuated poliovirus type 1.

Authors:  W P Glezen; G A Lamb; E A Belden; T D Chin
Journal:  Am J Epidemiol       Date:  1966-03       Impact factor: 4.897

9.  Poliomyelitis in the Netherlands 1958-69: the influence of a vaccination programme with inactivated poliovaccine.

Authors:  B Hofman
Journal:  Bull World Health Organ       Date:  1972       Impact factor: 9.408

10.  Surveillance and control of poliomyelitis in The Netherlands.

Authors:  H Bijkerk
Journal:  Rev Infect Dis       Date:  1984 May-Jun
View more
  7 in total

1.  Isolation of sabin-like polioviruses from wastewater in a country using inactivated polio vaccine.

Authors:  Sebastian Zurbriggen; Kurt Tobler; Carlos Abril; Sabine Diedrich; Mathias Ackermann; Mark A Pallansch; Alfred Metzler
Journal:  Appl Environ Microbiol       Date:  2008-07-18       Impact factor: 4.792

2.  Poliovirus-specific immunoglobulin A in persons vaccinated with inactivated poliovirus vaccine in The Netherlands.

Authors:  M M Herremans; A M van Loon; J H Reimerink; H C Rümke; H G van der Avoort; T G Kimman; M P Koopmans
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

3.  Genetic basis for immunological aberrations in poliovirus Sabin serotype 3 strains imported in the netherlands.

Authors:  J H Reimerink; H G van der Avoort; A M van Loon; M P Koopmans
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

Review 4.  Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis.

Authors:  Nicholas C Grassly
Journal:  J Infect Dis       Date:  2014-03-14       Impact factor: 5.226

5.  Assessing the stability of polio eradication after the withdrawal of oral polio vaccine.

Authors:  Michael Famulare; Christian Selinger; Kevin A McCarthy; Philip A Eckhoff; Guillaume Chabot-Couture
Journal:  PLoS Biol       Date:  2018-04-27       Impact factor: 8.029

6.  Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies.

Authors:  Sonia Resik; Alina Tejeda; Magile Fonseca; Carolyn Sein; Lai Heng Hung; Yenisleidys Martinez; Manuel Diaz; Hiromasa Okayasu; Roland W Sutter
Journal:  Trials Vaccinol       Date:  2015

7.  Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses.

Authors:  Siddhartha Kumar Bhaumik; Raveendra R Kulkarni; William C Weldon; Eduardo L V Silveira; Hasan Ahmed; Sivaram Gunisetty; Anmol Chandele; Rustom Antia; Harish Verma; Roland Sutter; Mark A Pallansch; M Steven Oberste; Francois Villinger; Walter Orenstein; Kaja Murali-Krishna
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.